report Latest Research, Reports
Advancements in Treating Moderate-to-Severe Plaque Psoriasis
27 November 2023
By UCB
Bimekizumab provides a rapid and long-term response in patients with moderate-to-severe plaque psoriasis. At the (EADV) 2023 Congress, three posters were presented reporting 3-year results from the Phase III/IIIb clinical trials of Bimekizumab.
Related content
report World Psoriasis Day, Reports
tool Advocacy, IFPA Forum
Collaborative research for psoriatic disease
tool Universal Health Coverage, Advocacy, Care and Treatment, IFPA Forum
Access to care and early detection of psoriatic disease
report Advocacy, Comorbidities, Living with Psoriatic Disease, Care and Treatment, Reports, IFPA Forum
External link
Tip sheet on how to manage psoriatic disease when planning to have a family from parents to future parents.
External link
Article from EUROPSO raises important points to remember when women are planning to have children.
Article Stigma, Care and Treatment
Advocating for Family Well-being in Psoriatic Disease